Among individuals with a diagnosis of type 2 diabetes across the United States, income level, hemoglobin A1c, and comorbidity burden were the primary patient-level drivers of the use of newer antidiabetic agents.
Non–guideline-concordant care for ovarian cancer was associated with higher all-cause and cancer-specific mortality, increased health care utilization, and increased Medicare expenditures, highlighting opportunities for improving cancer care in this vulnerable group.
Operator: Good morning and welcome to the ReWalk Robotics First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode for the duration of the call.
- NDA submission for etripamil in patients with PSVT currently on track for 3Q23
- Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on. | May 11, 2023